4-(2-乙氧羰基乙基)苯基硼酸 | 660440-57-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 4-(2-乙氧羰基乙基)苯基硼酸
• 中文别名: 4-[2-(乙氧基)乙基]苯硼酸
• 英文名称: (4-(3-ethoxy-3-oxopropyl)phenyl)boronic acid
• 英文别名: 4-(2-ethoxycarbonylethyl)phenylboronic acid；4-(2-ethoxycarbonyl-ethyl)-phenylboronic acid；4-(2-ethoxycarbonyl-ethyl)phenyl boronic acid；[4(2-ethoxycarbonylethyl)phenyl]boronic acid；[4-(3-ethoxy-3-oxopropyl)phenyl]boronic acid；4-[2-ethoxycarbonylethyl]phenylboronic acid
• CAS: 660440-57-3
• 化学式: C₁₁H₁₅BO₄
• mdl: MFCD04115652
• 分子量: 222.049
• InChiKey: PRCOGZNDLWXGHB-UHFFFAOYSA-N

物化性质

• 熔点：
  80-84°C
• 沸点：
  370.7±44.0 °C(Predicted)
• 密度：
  1.15±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.04
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2931900090
• 安全说明：
  S26,S36/37/39
• 危险性防范说明：
  P261,P264,P271,P280,P302+P352,P304+P340+P312,P305+P351+P338,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H315,H319,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
4-(2-Ethoxycarbonylethyl)phenylboronic acid
Product Name:
Synonyms: Ethyl 3-(4-boronophenyl)propionate

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
4-(2-Ethoxycarbonylethyl)phenylboronic acid
Ingredient name:
CAS number: 660440-57-3

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C11H15BO4
Molecular weight: 222.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(2-乙氧羰基乙基)苯基硼酸 在 二异丁基氢化铝 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 以70%的产率得到4-(3-羟基丙基)苯基硼酸
  参考文献：
  名称：

  使用硼酸的液-液分配进行多步相转换合成：具有扩展的兼容反应库的生产性标签

  摘要：

  标记：已开发出一种用于相位开关合成的系统。硼酸官能度用作与山梨糖醇络合的相标签，并有助于化合物在高pH下从有机溶剂转移到水中。然后可以将相标签用于生产性反应步骤中以生成目标产物，从而消除了通过硅胶色谱纯化的过程。

  DOI：

  10.1002/anie.200906710
• 作为产物：
  描述：

  对溴苯丙酸乙酯 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium acetate 、 二乙醇胺 作用下， 以 二甲基亚砜 、 异丙醇 为溶剂， 反应 30.0h， 生成 4-(2-乙氧羰基乙基)苯基硼酸
  参考文献：
  名称：

  与有机硼烷合成。十三。ω-（4-溴苯基）链烷酸的合成及其硼化

  摘要：

  通过氢硼化-热异构化-氧化，从1-溴-4-烯基苯5c - e获得ω-（4-溴苯基）链烷酸2c - e。通过与4,4,5,5,4'，4'，5'，5'-八甲基[2.2'] bi的交叉偶联反应，将它们的酯11c - e转化为相应的硼酸酯12c - e的高收率。离子液体[bmim] [BF 4 ]中的[[1,3,2]二恶硼硼烷基]（10）。使用频哪醇硼烷在离子液体中进行偶联反应可得到脱溴产物，并降低了12c - e的收率。3-（4-溴苯基）丙酸乙酯（通过与[2,2']双[[1,3,2]二氧杂硼烷基]交叉偶联，将7c）转化成3-（4- [1,3,2]二恶硼硼烷基）丙酸乙酯（9c）。

  DOI：

  10.1016/s0022-328x(02)01383-9

文献信息

• ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE
  申请人：Leivers Martin Robert

  公开号：US20090226398A1

  公开（公告）日：2009-09-10

  Disclosed are compounds and compositions of Formula (I), pharmaceutically acceptable salts and solvates thereof, and their preparation and uses for treating viral infections mediated at least in part by a virus in the Flaviviridae family of viruses.

  披露了公式(I)的化合物和组合物、药物可接受的盐和溶剂化物，以及它们的制备和使用，用于治疗至少部分由黄病毒科病毒家族中的病毒介导的病毒感染。
• 二氢嘧啶类化合物及其在药物中的应用
  申请人：广东东阳光药业有限公司

  公开号：CN109111451B

  公开（公告）日：2020-08-11

  本发明涉及一种二氢嘧啶类化合物及其作为药物的用途，尤其是作为治疗和预防乙型肝炎的药物的用途。具体地说，本发明涉及通式(I)或(Ia)所示的化合物或其对映异构体、非对映异构体、互变异构体、水合物、溶剂化物或药学上可接受的盐，其中各变量如说明书所定义。本发明还涉及通式(I)或(Ia)所示的化合物或其对映异构体、非对映异构体、互变异构体、水合物、溶剂化物或药学上可接受的盐作为药物的用途，尤其是作为治疗和预防乙型肝炎的药物的用途。
• Substituted Benzo-Imidazo-Pyrido-Diazepine Compounds
  申请人：Ashwell Mark A.

  公开号：US20120108574A1

  公开（公告）日：2012-05-03

  The present invention relates to substituted benzo-imidazo-pyrido-diazepine compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted benzo-imidazo-pyrido-diazepine compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.

  本发明涉及取代的苯并咪唑吡啶二氮杂化合物及其合成方法。本发明还涉及含有取代的苯并咪唑吡啶二氮杂化合物的药物组合物，以及通过向需要的主体施用这些化合物和药物组合物来治疗细胞增殖性障碍，如癌症的方法。
• [EN] DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE<br/>[FR] COMPOSÉS DIHYDROPYRIMIDINE ET UTILISATIONS DE CEUX-CI EN MÉDECINE
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2019001396A1

  公开（公告）日：2019-01-03

  Provided herein are a dihydropyrimidine compound and a pharmaceutical application thereof, especially the application used for treating and preventing HBV diseases. Specifically, provided herein is a compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein the variables of the formulas are as defined in the specification. Also provided herein is use of the compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof as a medicine, especially for treating and preventing HBV diseases.

  本文提供了一种二氢嘧啶化合物及其药物应用，特别是用于治疗和预防HBV疾病的应用。具体来说，本文提供了具有化学式（I）或（Ia）的化合物，或其对映体、异构体、互变异构体、水合物、溶剂合物或其药用可接受的盐，其中化学式的变量如规范中定义。本文还提供了将具有化学式（I）或（Ia）的化合物，或其对映体、异构体、互变异构体、水合物、溶剂合物或其药用可接受的盐用作药物的用途，特别是用于治疗和预防HBV疾病。
• Quinolines useful in treating cardiovascular disease
  申请人：Collini D. Michael

  公开号：US20050131014A1

  公开（公告）日：2005-06-16

  This invention provides compounds of formula I that are useful in the treatment or inhibition of LXR mediated diseases.

  本发明提供了公式I的化合物，其在治疗或抑制LXR介导的疾病方面是有用的。